J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S38–48PubMedCrossRef 18. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009 May; 123(5): 1412–20CrossRef 19. Vesikari T, Van Damme P, Giaquinto
C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008 May; 46(5): 615–8PubMedCrossRef 20. Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009. Wkly Epidemiol Rec 2009 Aug 7; 84(32): 325–32 21. GlaxoSmithKline. Rotarix (rotavirus vaccine, live, oral): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2011 Feb 22. McCormack PL, Keam SJ. Rotavirus vaccine RIX4414 (Rotarix): FK228 supplier a review of its use in the prevention of rotavirus gastroenteritis.
Paediatr Drugs 2009; 11(1): 75–88PubMedCrossRef 23. European Medicines Agency. Rotarix®: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000639/WC500054789.pdf [Accessed 2011 Mar 14] 24. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during DMXAA ic50 the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007 Nov 24; 370: 1757–63PubMedCrossRef 25. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan; 354(1): 11–22PubMedCrossRef 26. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004 Oct; 23(10): 937–43PubMedCrossRef 27. Lambert SB, Faux CE, Hall L, et al. Early evidence for
direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009 Aug 3; 191(3): 157–60PubMed 28. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28: 7507–13PubMedCrossRef 29. Braeckman T, Van Herck K, Raes (-)-p-Bromotetramisole Oxalate M, et al. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S21–4PubMed 30. Raes M, Strens D, Vergison A, et al. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011; 30(7): e120–5PubMedCrossRef 31. Plosker GL. Pentavalent rotavirus vaccine (Rota Teq®): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 2010 Jun 18; 70(9): 1165–88PubMedCrossRef 32. Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination.